L. Debouverie, L. Rumbach, and P. Clavelou, Revue neurologique, vol.163, pp.637-645, 2007.

, Interferon beta-1b is effective in relapsingremitting multiple sclerosis. I. Clinical results of a multicenter, randomized, doubleblind, placebo-controlled trial, The IFNB Multiple Sclerosis Study Group, vol.43, pp.655-61, 1993.

L. D. Jacobs, D. L. Cookfair, R. A. Rudick, R. M. Herndon, J. R. Richert et al.,

F. E. Munschauer, R. L. Priore, P. M. Pullicino, B. J. Scherokman, and R. H. Whitham, Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis, Ann Neurol, vol.39, pp.285-94, 1996.

, PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis, Lancet, vol.352, pp.1498-504, 1998.

R. L. Knobler, J. I. Greenstein, K. P. Johnson, F. D. Lublin, H. S. Panitch et al., Systemic recombinant human interferon-beta treatment of relapsing-remitting multiple sclerosis: pilot study analysis and six-year follow-up, J Interferon Res, vol.13, issue.5, pp.333-373, 1993.

L. Durelli, M. R. Bongioanni, R. Cavallo, B. Ferrero, R. Ferri et al., Chronic systemic high-dose recombinant interferon alfa-2a reduces exacerbation rate, MRI signs of disease activity, and lymphocyte interferon gamma production in relapsing-remitting multiple sclerosis, Neurology, vol.44, issue.3, pp.406-419, 1994.

M. W. Nortvedt, T. Riise, K. M. Myhr, and H. I. Nyland, Hanestad BRType I interferons and the quality of life of multiple sclerosis patients. Results from a clinical trial on interferon alfa-2a, Mult Scler, vol.5, issue.5, pp.317-339, 1999.

, The Once Weekly Interferon for MS Study Group. Evidence of interferon beta-1a dose response in relapsing-remitting MS: the OWIMS Study, Neurology, vol.53, issue.4, pp.679-86, 1999.

C. Polman, F. Barkhof, L. Kappos, C. Pozzilli, R. Sandbrink et al.,

, European Oral Interferon Beta-1a in Relapsing-Remitting MS Study GroupOral interferon beta-1a in relapsing-remitting multiple sclerosis: a double-blind randomized study, Mult Scler, vol.9, issue.4, pp.342-350, 2003.

M. B. Bornstein, A. Miller, S. Slagle, M. Weitzman, H. Crystal et al., A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis, N Engl J Med, vol.317, issue.7, pp.408-422, 1987.

M. B. Bornstein, A. Miller, S. Slagle, M. Weitzman, E. Drexler et al., A placebo-controlled, double-blind, randomized, twocenter, pilot trial of Cop 1 in chronic progressive multiple sclerosis, 1991.

K. P. Johnson, B. R. Brooks, J. A. Cohen, C. C. Ford, J. Goldstein et al., Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group, Neurology, vol.45, issue.7, pp.1268-76, 1995.

G. Comi, M. Filippi, and J. S. Wolinsky, European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group, Annals of neurology, vol.49, issue.3, pp.290-297, 2001.

, European Study Group on interferon ?-1b in secondary progressive MS. Placebocontrolled multicenter randomized trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis, Lancet, vol.352, pp.1491-1498, 1998.

, The North American Study Group on Interferon beta-1b in Secondary Progressive MS. Interferon beta-1b in secondary progressive MS. Results from a 3-year controlled study, Neurology, vol.63, pp.1788-95, 2004.

, Secondary progressive efficacy clinical trial of recombinant interferon beta 1-a in MS (Spectrims) study group. Randomized controlled trial of interferon beta 1a in secondary progressive MS. Clinical results, Neurology, vol.56, pp.1496-504, 2001.

J. A. Cohen, Benefit of interferon beta-1a on MSFC progression in secondary progressive MS, Neurology, vol.59, pp.679-87, 2002.

O. Andersen, Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis, J Neurol Neurosurg Psychiatry, vol.75, pp.706-716, 2004.

L. Kappos, Final analysis of the European multicenter trial on INF-1b in secondary progressive MS, Neurology, vol.57, pp.1969-75, 2001.

L. Kappos, Interferon beta-1b in secondary progressive MS. A combined analysis of the two trials, Neurology, vol.63, pp.1779-87, 2004.

L. Kappos, Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes, Neurology, vol.67, pp.1-8, 2006.

L. D. Jacobs, R. W. Beck, J. H. Simon, R. P. Kinkel, C. M. Brownscheidle et al., Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis, N Engl J Med, vol.343, pp.898-904, 2000.

G. Comi, M. Filippi, F. Barkhof, L. Durelli, G. Edan et al., Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised sudy, Lancet, vol.357, issue.9268, pp.1576-82, 2001.

G. Comi, V. Martinelli, M. Rodegher, L. Moiola, O. Bajenaru et al., Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomized, double-blind, placebo-controlled trial, Lancet, vol.374, issue.9700, pp.1503-1514, 2009.

C. H. Polman, Diagnostic Criteria for multiple Sclerosis: 2005 Revisions to the "McDonald Criteria, Ann Neurol, vol.58, pp.840-846, 2005.

, The PRISMS Study group & the University of British Columbia MS/MRI analysis group. PRISMS-4: Long term efficacy of interferon beta-1a in relapsing MS, Neurology, vol.56, pp.1628-1664, 2001.

J. Oger, G. Francis, and P. Chang, Prospective assessment of changing from placebo to IFN beta-1a in relapsing MS : The PRISMS study, J Neurol Sci, vol.237, pp.45-52, 2005.

R. A. Rudick, Estimating long-term effects of disease-modifying drug therapy in multiple sclerosis patients, Multiple Sclerosis, vol.11, pp.626-660, 2005.

G. Ebers, A. Reder, A. Traboulsee, and D. Li, Long term follow-Up of the Original Interferon-?1b Trial in Multiple Sclerosis: Design and Lessons From a 16-Year Observational Study, Clinical Therapeutics, vol.31, issue.8, pp.1724-1760, 2009.

K. P. Johnson, B. R. Brooks, C. C. Ford, A. Goodman, J. Guarnaccia et al., Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years, Multiple sclerosis, vol.6, issue.4, pp.255-66, 2000.

K. P. Johnson, B. R. Brooks, C. C. Ford, A. D. Goodman, R. P. Lisak et al., Glatiramer acetate (Copaxone): comparison of continuous versus delayed therapy in a six-year organized multiple sclerosis trial, Multiple sclerosis, vol.9, issue.6, pp.585-91, 2003.

K. P. Johnson, C. C. Ford, R. P. Lisak, and J. S. Wolinsky, Neurologic consequence of delaying glatiramer acetate therapy for multiple sclerosis: 8-year data, Acta neurologica Scandinavica, vol.111, issue.1, pp.42-49, 2005.

C. C. Ford, K. P. Johnson, R. P. Lisak, H. S. Panitch, G. Shifronis et al., A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients, Multiple sclerosis, vol.12, issue.3, pp.309-329, 2006.

M. Rovaris, G. Comi, M. A. Rocca, P. Valsasina, D. Ladkani et al., Long-term followup of patients treated with glatiramer acetate: a multicentre, multinational extension of the European/Canadian double-blind, placebo-controlled, MRI-monitored trial, Multiple sclerosis, vol.13, issue.4, pp.502-510, 2007.

R. Kinkel and . Group, Interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event, Neurology, vol.66, issue.5, pp.678-84, 2006.

L. Kappos, Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis : a 3-year follow-up analysis of the BENEFIT study, Lancet, vol.370, pp.389-97, 2007.

L. Kappos, Long-term of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis : 5-year active treatment extension of the phase 3 BENEFIT trial, Lancet Neurology, vol.8, issue.11, pp.987-97, 2009.

J. Rio, Interferon b in relapsing-remitting multiple sclerosis. An eight year experience in a specialist multiple sclerosis center, J Neurol, vol.252, pp.795-800, 2005.

G. Coppola, Long term clinical experience with weekly interferon beta-1a in relapsing multiple sclerosis, Europ J of Neurol, vol.13, pp.1014-1035, 2006.

M. G. Brown, S. Kirby, and C. Skedgel, How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?, Neurology, vol.69, pp.1498-507, 2007.

M. Trojano, New Natural History of interferon b Treated Relapsing Multiple Sclerosis, Ann Neurol, vol.61, pp.300-306, 2007.

P. J. Veugelers, Disease progression among multiple sclerosis patients before and during a diseasemodifying drug program: a longitudinal population-based evaluation, Multiple Sclerosis, vol.15, issue.11, pp.1286-94, 2009.

C. J. Sindic, P. Seeldrayers, V. Gaer, L. , D. Smet et al., Longterm follow up of glatiramer acetate compassionate use in Belgium, Acta neurologica Belgica, vol.105, issue.2, pp.81-86, 2005.

M. Debouverie, T. Moreau, C. Lebrun, O. Heinzlef, F. Brudon et al., A longitudinal observational study of cohort of patients with relapsing-remitting multiple sclerosis treated with glatiramer acetate, Eur J Neurol, vol.14, issue.11, pp.1266-74, 2007.

M. Trojano, F. Pellegrini, and . Destat, for the Italian Multiple Sclerosis Database Network (MSDN) Group. Real-Life Impact of Early Interferon Therapy in Relapsing Multiple Sclerosis, Ann Neurol, vol.66, pp.513-520, 2009.

L. Kappos, Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS, Neurology, vol.67, pp.944-953, 2006.

M. Clanet, L. Kappos, and H. P. Hartung, Hohlfeld R and The European IFNb-1a DoseComparison Study Investigators. Interferon b-1a in relapsing multiple sclerosis: fouryear extension of the European IFNb-1a Dose-Comparison Study, Multiple Sclerosis, vol.10, pp.139-144, 2004.

R. M. Herndon, L. D. Jacobs, and M. E. Coats, Results of an ongoing, open-label, safety extension study of interferon beta-1a (Avonex) treatment in multiple sclerosis, Int J MS Care, vol.1, pp.1-6, 1999.

C. Caon, M. Din, W. Ching, A. Tselis, R. Lisak et al., Clinical course after change of immunomodulating therapy in relapsing-remitting multiple sclerosis, Eur J Neurol, vol.13, issue.5, pp.471-475, 2006.

A. Carra, P. Onaha, G. Luetic, M. Burgos, E. Crespo et al., Therapeutic outcome 3 years after switching og immunomodulatory therapies in patients with relapsing-remitting multiple sclerosis in Argentina, Eur J Neurol, vol.15, pp.386-93, 2008.

H. L. Zwibel, Glatiramer acetate in treatment-naive and prior interferon-beta-1btreated multiple sclerosis patients, Acta Neurologica Scandinavica, vol.113, issue.6, pp.378-86, 2006.
DOI : 10.1111/j.1600-0404.2006.00627.x

F. Patti, Effects of interferon beta-1a and-1b over time: 6-year results of an observational head-to-head study, Acta Neurol Scand, vol.113, pp.241-248, 2006.

O. 'rourke, K. Walsh, C. Hutchinson, and M. , Outcome of beta-interferon treatment in relapsing-remitting multiple sclerosis: a Bayesian analysis, J Neurol, vol.254, pp.1547-54, 2007.

J. K. Lunceford and M. Davidian, Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative study, Stat Med, vol.23, pp.2937-2960, 2004.

D. Rb, Propensity score methods for bias reduction in the comparison of treatment to a non-randomized control group, Stat Med, vol.17, pp.2265-2281, 1998.

C. Confavreux, D. Compston, and O. R. Hommes, EDMUS, a European database for multiple sclerosis, J Neurol Neurosurg Psychatry, vol.55, pp.671-676, 1992.
DOI : 10.1136/jnnp.55.8.671

URL : https://jnnp.bmj.com/content/55/8/671.full.pdf

C. M. Poser, D. W. Paty, and L. Scheinberg, New diagnostic criteria for multiple sclerosis : guidelines for research protocols, Ann Neurol, vol.13, pp.227-231, 1983.
DOI : 10.1002/ana.410130302

W. I. Mcdonald, A. Compston, and G. Edan, Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis, Ann Neurol, vol.50, pp.121-127, 2001.

C. H. Polman, S. C. Reingold, and G. Edan, Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria, Ann Neurol, vol.59, issue.4, pp.727-728, 2006.
DOI : 10.1002/ana.22366

URL : http://europepmc.org/articles/pmc3084507?pdf=render

J. F. Kurtzke, Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS), Neurology, vol.33, pp.1444-52, 1983.
DOI : 10.1212/wnl.33.11.1444

URL : http://n.neurology.org/content/33/11/1444.full.pdf

E. Leray, J. Yaouanq, L. Page, E. Coustans, M. Laplaud et al., Evidence for a two-stage disability progression in multiple sclerosis, Brain, vol.133, pp.1900-1913, 2010.
DOI : 10.1093/brain/awq076

URL : https://academic.oup.com/brain/article-pdf/133/7/1900/927470/awq076.pdf

S. Schneeweiss, J. A. Rassen, R. J. Glynn, J. Avorn, H. Mogun et al., Highdimensional propensity score adjustment in studies of treatment effects using health care claims data, Epidemiology, vol.20, issue.4, pp.523-527, 2009.

B. G. Weinshenker, B. Bass, and G. P. Rice, The natural history of multiple sclerosis: a geographically based study. 2. Predictive values of the early clinical course, Brain, vol.6, pp.1419-1447, 1989.

C. Confavreux, S. Vukusic, T. Moreau, and P. Adeleine, Relapses and progression of disability in multiple sclerosis, New England Journal of Medicine, vol.343, pp.1430-1438, 2000.

C. Confavreux and S. Vukusic, Adeleine P. early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process, Brain, vol.126, pp.770-82, 2003.

S. J. Pittock, W. T. Mayr, and R. L. Mcclelland, Disability profile of MS did not change over 10 years in a population-based prevalence cohort, Neurology, vol.62, pp.601-607, 2004.

H. Tremlett, D. Paty, and V. Devonshire, Disability progression in multiple sclerosis is slower than previously reported, Neurology, vol.66, pp.172-179, 2006.
DOI : 10.1212/01.wnl.0000194259.90286.fe

M. Brown, P. Andreou, S. Kirby, and J. Murray, EDSS natural history atlas: MS disability progression in Nova Scotia, ECTRIMS conference, vol.14, issue.1, p.540, 1979.

M. Debouverie, S. Pittion-vouyovitch, and L. S. Guillemin-f-for, Natural history of multiple sclerosis in a population-based cohort, Eur J Neurol, vol.15, pp.916-937, 2008.

F. D. Lublin and S. C. Reingold, and the National Multiple Sclerosis Society (USA) Task Force on Placebo-Controlled Clinical Trials in MS. Placebo-controlled clinical trials in multiple sclerosis: ethical considerations, Ann Neurol, vol.49, pp.677-81, 2001.

S. Schwid and C. T. Bever, The cost of delaying treatment in multiple sclerosis: what is lost is not regained, Neurology, vol.56, p.1620, 2001.

A. Laupacis and M. Mamdani, Observational studies of treatment effectiveness: some cautions, Ann Intern Med, vol.140, pp.923-927, 2004.

I. Yanovitzky, E. Zanutto, and R. Hornik, Estimating causal effects of public health education campaigns using propensity score methodology, Eval Program Plann, vol.28, pp.209-229, 2005.

D. Y. Lin, B. M. Psaty, and R. A. Krommal, Assessing the sensitivity of regression results to unmeasured confounders n observational studies, Biometrics, vol.54, pp.948-63, 1998.

L. E. Braitman and P. R. Rosenbaum, Rare outcomes, common treatments: analytic strategies using propensity scores, Ann Intern Med, vol.137, pp.693-698, 2002.

H. Tremlett, Y. Zhao, P. Rieckmann, and M. Hutchinson, New perspectives in the natural history of multiple sclerosis, Neurology, vol.74, pp.2004-2019, 2010.

C. Confavreux and S. Vukusic, Age at disability milestones in multiple sclerosis, Brain, vol.129, pp.595-605, 2006.

N. Vu, , vol.21, 2011.

A. Thèse, , p.3581

L. Nancy,

C. Madame and . Capdeville-atkinson,